Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors

Adrian C. Johnston,Gretchen M. Alicea,Cameron C. Lee,Payal V. Patel,Eban A. Hanna,Eduarda Vaz,André Forjaz,Zeqi Wan,Praful R. Nair,Yeongseo Lim,Tina Chen,Wenxuan Du,Dongjoo Kim,Tushar D. Nichakawade,Vito W. Rebecca,Challice L. Bonifant,Rong Fan,Ashley L. Kiemen,Pei-Hsun Wu,Denis Wirtz

DOI: https://doi.org/10.1101/2023.12.13.571595

2024-03-26

Abstract:Chimeric antigen receptor (CAR) T cells express antigen-specific synthetic receptors, which upon binding to cancer cells, elicit T cell anti-tumor responses. CAR T cell therapy has enjoyed success in the clinic for hematological cancer indications, giving rise to decade-long remissions in some cases. However, CAR T therapy for patients with solid tumors has not seen similar success. Solid tumors constitute 90% of adult human cancers, representing an enormous unmet clinical need. Current approaches do not solve the central problem of limited ability of therapeutic cells to migrate through the stromal matrix. We discover that T cells at low and high density display low- and high-migration phenotypes, respectively. The highly migratory phenotype is mediated by a paracrine pathway from a group of self-produced cytokines that include IL5, TNFα, IFNγ, and IL8. We exploit this finding to “lock-in” a highly migratory phenotype by developing and expressing receptors, which we call velocity receptors (VRs). VRs target these cytokines and signal through these cytokines’ cognate receptors to increase T cell motility and infiltrate lung, ovarian, and pancreatic tumors in large numbers and at doses for which control CAR T cells remain confined to the tumor periphery. In contrast to CAR therapy alone, VR-CAR T cells significantly attenuate tumor growth and extend overall survival. This work suggests that approaches to the design of immune cell receptors that focus on migration signaling will help current and future CAR cellular therapies to infiltrate deep into solid tumors.

Immunology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the efficacy of CAR - T cell therapy in solid tumors. Specifically, researchers have found that currently, CAR - T cell therapy has achieved remarkable success in the treatment of hematological malignancies, but has poor results in the treatment of solid tumors. The main reason is that CAR - T cells are difficult to effectively penetrate into solid tumors because solid tumors contain a high - density and complex extracellular matrix (ECM), which forms a physical barrier and hinders the migration of T cells.

To overcome this challenge, researchers have developed a new strategy, that is, by engineering self - propelling tumor - infiltrating CAR - T cells, using synthetic velocity receptors (VRs). These velocity receptors can enable CAR - T cells to exhibit higher migratory ability in the solid tumor microenvironment, thus more effectively penetrate into the tumor interior and play an anti - tumor role.

Specifically, researchers have found that T cells exhibit low - migration and high - migration phenotypes under low - density and high - density conditions respectively, and the high - migration phenotype is mediated by a set of autocrine cytokines (such as IL5, TNFα, IFNγ and IL8). Based on this finding, they designed and expressed velocity receptors (VRs), which can target these cytokines and increase the migratory ability of T cells through their corresponding receptor signaling pathways. Experimental results show that VR - CAR - T cells (CAR - T cells expressing VRs) can massively penetrate into the tumor core in multiple solid tumor models (including lung cancer, ovarian cancer and pancreatic cancer), and significantly inhibit tumor growth and prolong overall survival.

In conclusion, this paper aims to solve the current limitations of CAR - T cell therapy in the treatment of solid tumors by enhancing the migratory ability of CAR - T cells, thereby improving its clinical efficacy.